Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPRX 106

Next Previous
Search
Drug Profile

OPRX 106

Alternative Names: Anti-TNF therapeutic - Protalix Biotherapeutics; Anti-tumour necrosis factor therapeutic - Protalix Biotherapeutics; OPRX-106; pr-anti-TNF; PRX-106; Recombinant TNFR2-Fc fusion protein - Protalix Biotherapeutics; rTNFR2-Fc - Protalix Biotherapeutics; rTNFRII-Fc - Protalix Biotherapeutics

Latest Information Update: 23 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protalix Biotherapeutics
  • Developer Protalix BioTherapeutics
  • Class Anti-inflammatories; Antirheumatics; Hepatoprotectants; Recombinant fusion proteins
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 10 stimulants; Regulatory T-lymphocyte stimulants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Crohn's disease; Fatty liver; Hepatitis; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 23 Feb 2023 Discontinued - Phase-II for Ulcerative colitis in Bulgaria (PO) (Protalix Biotherapeutics pipeline, February 2023)
  • 23 Feb 2023 Discontinued - Phase-II for Ulcerative colitis in Israel (PO) (Protalix Biotherapeutics pipeline, February 2023)
  • 23 Feb 2023 Discontinued - Preclinical for Autoimmune disorders in Israel (PO) (Protalix Biotherapeutics pipeline, February 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top